Clinical Trial Update: Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 trial update for AB002 (E-WE Thrombin) in end-stage renal disease patients on chronic hemodialysis; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Thrombosis

Drugs mentioned

• AB002 (E-WE Thrombin) (AB002)

Snippet

Sponsor: Aronora, Inc. | Conditions: End Stage Renal Disease, Thrombosis | Phase 2 | Status: COMPLETED | Results posted: 2022-03-15